The European Association for the Study of the Liver (EASL) annual meeting was held in Milan, Italy during 23-27 April 2008. This is a major international clinical symposium that showcases findings from hepatitis B and C treatment trials. The Clinical Care Options (CCO) has prepared an independent coverage of this meeting available at this link Open Link

Audio Expert Highlights From EASL in MP3 Format Click to Access

New Advances in Hepatitis C — Click a link below to access a Capsule Summary Click Here

COPILOT Final Results: Maintenance Therapy With Peginterferon Alfa-2b Associated With Improved Event-Free Survival in Patients With Cirrhosis and Portal Hypertension Click Here

RVR a Better Predictor of SVR Than HCV Genotype in HCV-Infected Patients With Peginterferon alfa-2a Plus Ribavirin Click Here

HCV Genotype 2/3 Patients With Low Baseline Platelet Count or High BMI Should Not Receive Shortened 12-Week Course of Peginterferon alfa-2b plus Weight-Based Ribavirin due to Higher Rates of Relapse Click Here

Cirrhosis Regression During HCV Therapy Associated With Improved Liver-Related Morbidity, Mortality During Long-term Follow-up Click Here